title: [Seasonal and perennial allergic rhinoconjunctivitis].
abstract: Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) as well as intermittent and persistent allergic rhinitis are widespread diseases. Because a combined occurrence of ocular and nasal symptoms is very common the summarising term allergic rhinoconjunctivitis is frequently used. SAC and PAC representing the two acute forms of allergic conjunctivitis account for more than 90 % of all cases of allergic conjunctivitis. Compared to the chronic forms of allergic conjunctivitis their course of disease is milder. Nevertheless because of their high prevalence and the proven influence on patients' quality of life they possess clinical and socioeconomic relevance. Allergic rhinoconjunctivitis is caused by a type 1 IgE-mediated hypersensitivity reaction that is provoked by aeroallergens in the majority of cases. The pathognomonic sign is itching. Besides, typical ocular findings are chemosis, conjunctival injection, watery secretion and lid swelling. Otorhinolaryngologists' findings include rhinorrhea, postnasal drip and sneezing. Problems in breathing through the nose resulting from nasal obstruction can cause impaired nighttime sleep and daytime somnolence. In addition to a reduction of allergen exposure by modification of environment and life style factors, in mild forms of SAC and PAC artificial tears are recommended. Topical antihistamines can generate rapid relief from acute symptoms and itching. Topical mast cell stabilisers however provide long-term effects. Dual action drugs that combine antihistamines and mast cell stabilisers show increased patient compliance due to reduced application frequency. Use of topical steroids should be cautious and only temporary. For prolonged treatment periods unpreserved anti-allergic eye-drops should be preferred. Combined topical antihistamines and new-generation topical nasal steroids often used by otorhinolaryngologists demonstrate a good safety profile without systemic side effects. In summary, allergic rhinoconjunctivitis represents a common disease pattern that can be treated effectively. Once it is diagnosed correctly targeted treatment results in improved patients' quality of life quickly.
authors.affiliation: Augenklinik, Universitätsklinikum Düsseldorf, Düsseldorf.
authors.forename: K
authors.initials: K
authors.lastname: Schröder
authors.affiliation: Augenklinik, Universitätsklinikum Düsseldorf, Düsseldorf.
authors.forename: D
authors.initials: D
authors.lastname: Finis
authors.affiliation: Hautklinik, Universitätsklinikum Düsseldorf, Düsseldorf.
authors.forename: S
authors.initials: S
authors.lastname: Meller
authors.affiliation: Hautklinik, Universitätsklinikum Düsseldorf, Düsseldorf.
authors.forename: B A
authors.initials: BA
authors.lastname: Buhren
authors.affiliation: HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf.
authors.forename: M
authors.initials: M
authors.lastname: Wagenmann
authors.affiliation: Augenklinik, Universitätsklinikum Düsseldorf, Düsseldorf.
authors.forename: G
authors.initials: G
authors.lastname: Geerling
mesh_terms: D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003233:Conjunctivitis, Allergic / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*; D005123:Eye / Q000276:immunology; D005858:Germany; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D018448:Models, Immunological; D065631:Rhinitis, Allergic / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy*
chemical_list: D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D006633:Histamine Antagonists